Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBYI Puma Biotechnology	$3.55 -0.3%	$3.33	$2.23 ▼ $4.13	$177.68M	1.29	414,099 shs	127,438 shs
PHAR Pharming Group	$10.38 -2.5%	$10.42	$6.65 ▼ $12.61	$719.77M	0.02	6,122 shs	344 shs
RCKT Rocket Pharmaceuticals	$2.90 +0.6%	$4.50	$2.19 ▼ $26.98	$309.68M	0.67	2.21 million shs	1.75 million shs
TRVI Trevi Therapeutics	$5.90 -1.4%	$6.28	$2.36 ▼ $7.48	$697.89M	0.46	1.42 million shs	993,025 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBYI Puma Biotechnology	0.00%	+6.61%	-0.28%	+22.41%	+17.55%
PHAR Pharming Group	0.00%	-4.12%	-14.64%	+32.82%	+23.13%
RCKT Rocket Pharmaceuticals	0.00%	+14.47%	-0.82%	-43.44%	-85.54%
TRVI Trevi Therapeutics	0.00%	+4.91%	-10.40%	-2.55%	+120.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PBYI Puma Biotechnology	4.1894 of 5 stars	3.5	2.0	0.0	1.9	4.2	3.1
PHAR Pharming Group	2.9053 of 5 stars	3.5	5.0	0.0	2.4	0.0	0.6
RCKT Rocket Pharmaceuticals	4.8562 of 5 stars	4.2	2.0	4.7	1.7	5.0	1.3
TRVI Trevi Therapeutics	3.2941 of 5 stars	4.7	1.0	0.0	3.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PBYI Puma Biotechnology	3.00	Buy	$7.00	97.18% Upside
PHAR Pharming Group	3.00	Buy	$30.00	189.02% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	542.27% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.88	254.05% Upside

Current Analyst Ratings Breakdown

Latest PBYI, TRVI, RCKT, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PBYI Puma Biotechnology	$230.50M	0.76	$0.85 per share	4.20	$1.88 per share	1.89
PHAR Pharming Group	$297.20M	2.38	$0.07 per share	142.73	$3.25 per share	3.19
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PBYI Puma Biotechnology	$30.28M	$0.77	4.61	9.34	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	346.00	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/6/2025 (Estimated)

Latest PBYI, TRVI, RCKT, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PBYI Puma Biotechnology	0.11	1.53	1.43
PHAR Pharming Group	0.39	2.76	2.00
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PBYI Puma Biotechnology	61.29%
PHAR Pharming Group	0.03%
RCKT Rocket Pharmaceuticals	98.39%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
PBYI Puma Biotechnology	23.30%
PHAR Pharming Group	2.07%
RCKT Rocket Pharmaceuticals	24.76%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

PBYI, TRVI, RCKT, and PHAR Headlines

Recent News About These Companies

Cantor Fitzgerald Predicts TRVI FY2025 Earnings

July 5 at 2:55 AM | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?

July 3 at 1:13 PM | marketbeat.com

Analysts Offer Predictions for TRVI FY2025 Earnings

July 3 at 7:27 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Cantor Fitzgerald

July 3 at 2:47 AM | americanbankingnews.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2 at 9:36 AM | msn.com

TRVI Trevi Therapeutics, Inc. - Seeking Alpha

July 1, 2025 | seekingalpha.com

Cantor Fitzgerald Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)

July 1, 2025 | marketbeat.com

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

July 1, 2025 | prnewswire.com

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

June 26, 2025 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4% - Time to Sell?

June 25, 2025 | marketbeat.com

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Leerink Partnrs Has Bullish Forecast for TRVI Q2 Earnings

June 13, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9, 2025 | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 6, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI, TRVI, RCKT, and PHAR Company Descriptions

Puma Biotechnology NASDAQ:PBYI

$3.55 -0.01 (-0.28%)

Closing price 07/3/2025 03:21 PM Eastern

Extended Trading

$3.54 0.00 (-0.14%)

As of 07/3/2025 04:09 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Pharming Group NASDAQ:PHAR

$10.38 -0.27 (-2.54%)

As of 07/3/2025 03:09 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.90 +0.02 (+0.56%)

Closing price 07/3/2025 03:49 PM Eastern

Extended Trading

$2.89 -0.01 (-0.21%)

As of 07/3/2025 04:55 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Trevi Therapeutics NASDAQ:TRVI

$5.90 -0.08 (-1.40%)

As of 07/3/2025 03:48 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time